Care of the HIV-Positive Patient in the Emergency Department in the Era of Highly Active Antiretroviral Therapy

Annals of Emergency Medicine

Volumn 52, Issue 3, 2008, Pages 274-285

  Venkat, Arvind ^a   Piontkowsky, David M ^a   Cooney, Robert R ^a   Srivastava, Adarsh K ^a   Suares, Gregory A ^a   Heidelberger, Cory P ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMIODARONE; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRITIDE; FLECAINIDE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; PHENYTOIN; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

ABDOMINAL PAIN; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; DEPRESSION; DIARRHEA; DYSLIPIDEMIA; EMERGENCY CARE; EMERGENCY WARD; ENDOCRINE DISEASE; EYE DISEASE; FATTY LIVER; FEVER; GASTROINTESTINAL DISEASE; HEADACHE; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERPIGMENTATION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INJECTION SITE REACTION; KIDNEY DISEASE; KIDNEY FAILURE; LACTIC ACIDOSIS; LIPODYSTROPHY; LIVER FAILURE; LIVER TOXICITY; LUNG DISEASE; MENTAL DISEASE; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEPHROTOXICITY; ORTHOSTATIC HYPOTENSION; PANCREATITIS; PATIENT CARE; PERIPHERAL NEUROPATHY; PNEUMONIA; PR INTERVAL; PRIORITY JOURNAL; PSYCHOSIS; RASH; REVIEW; SIDE EFFECT; SKIN DISCOLORATION; STEVENS JOHNSON SYNDROME; SUICIDAL IDEATION; UROLITHIASIS; VOMITING;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; DRUG INTERACTIONS; EMERGENCY SERVICE, HOSPITAL; GASTROINTESTINAL DISEASES; HIV INFECTIONS; HUMANS; MENTAL DISORDERS; MUSCULOSKELETAL DISEASES; RISK FACTORS; SKIN DISEASES;

EID: 49549121629     PISSN: 01960644     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annemergmed.2008.01.324     Document Type: Review

References (97)

1. Glynn M., and Rhodes P. Estimated HIV prevalence in the United States at the end of 2003 (2005) Presented at the National HIV Prevention Conference, Atlanta, GA.
2. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report 2005 (2007), US Department of Health and Human Services, Atlanta, GA CDC
3. Lima V., Hogg R., Harrigan P., et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 21 (2007) 685-692
4. Palella Jr. F., Delaney K., Moorman A., et al. Declining morbidity and mortality among patients with advanced HIV infection. HIV outpatient study investigators. N Engl J Med 338 (1998) 853-860
5. Talan D., and Kennedy C. The management of HIV-related illness in the emergency department. Ann Emerg Med 20 (1991) 1355-1365
6. Guss D. The acquired immune deficiency syndrome: an overview for the emergency physician, part 1. J Emerg Med 12 (1994) 375-384
7. Guss D. The acquired immune deficiency syndrome: an overview for the emergency physician, part 2. J Emerg Med 12 (1994) 491-497
8. Pulvirenti J. Inpatient care of the HIV infected patient in the highly active antiretroviral therapy (HAART) era. Curr HIV Res 3 (2005) 133-145
9. Pulivrenti J., Muppidi U., Glowacki R., et al. Changes in HIV-related hospitalizations during the HAART era in an inner city hospital. AIDS Read 17 (2007) 390-394 397-401.
10. Kozak L., McCarthy E., and Moien M. Patterns of hospital use by patients with diagnoses related to HIV infection. Public Health Reports 106 (1993) 571-581
11. Kozak L., DeFrances C., and Hall M. National hospital discharge survey: 2004 annual summary with detailed diagnosis and procedure data. Vital Health Stat 13 162 (2006) 1-209
12. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services. http://www.aidsinfo.nih.gov December 1 2007:1-136. Accessed December 20, 2007.
13. Bartlett J., and Gallant J. Medical Management of HIV Infection (2007), Johns Hopkins Medicine Health Publishing Business Group, Baltimore, MD
14. Falco V., Rodriguez D., Ribera E., et al. Severe nucleoside-associated lactic acidosis in HIV-infected patients: a report of 12 patients and review of the literature. Clin Infect Dis 34 (2002) 838-846
15. Lalezari J., Goodrich J., DeJesus E., et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR-5-tropic HIV-1: 24 week results of a phase 2b/3 study in the US and Canada (2007) Presented at the 14th Conference on Retroviruses and Opportunistic Infection, Los Angeles, CA.
16. Grinztejn B., Nguyen B., Katlama C., et al. Safety and efficacy of HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment experienced patients with multi-drug resistant virus: a phase II randomized controlled trial. Lancet 369 (2007) 1261-1269
17. Shelburne S., Visnegarwala F., Darcourt J., et al. Incidence and risk factors for IRIS during HAART. AIDS 19 (2005) 399-405
18. Crum-Cianflone N. Immune reconstitution inflammatory syndromes: what's new?. AIDS Read 16 (2006) 199-206
19. Oh J., and Hegele R. HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect Dis 7 (2007) 787-796
20. Stein J., Klein M., Bellehumeur J., et al. Use of HIV-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 104 (2001) 257-262
21. Friis-Moller N., Sabin C., Weber R., et al., DAD Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349 (2003) 1993-2003
22. Triant V., Lee H., Hadigan C., et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 92 (2007) 2506-2512
23. Friis-Moller N., Reiss P., Sabin C., et al., DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 356 (2007) 1723-1735
24. DeCastro S., Migliau G., Silvestri A., et al. Heart involvement in AIDS: a prospective study during various stages of the disease. Eur Heart J 13 (1992) 1452-1459
25. Sudano I., Spieker L., Noll G., et al. Cardiovascular disease in HIV infection. Am Heart J 151 (2006) 1147-1155
26. Fine M., Auble T., Yealy D., et al. A prediction rule to identify low risk patients with community-acquired pneumonia. N Engl J Med 336 (1997) 243-250
27. Wolff A., and O'Donnell A. Pulmonary manifestations of HIV infection in the era of highly active antiretroviral therapy. Chest 120 (2001) 1888-1893
28. Lazarous D., and O'Donnell A. Pulmonary infections in the HIV-infected patient in the era of highly active antiretroviral therapy: an update. Curr Infect Dis Rep 9 (2007) 228-232
29. Centers for Disease Control and Prevention. Treating opportunistic infections in HIV-infected adults and adolescents. MMWR Morb Mortal Wkly Rep 53 (2004) 1-112
30. Crothers K., Butt A., Gibert C., et al. Increased COPD among HIV-positive compared to HIV-negative veterans. Chest 130 (2006) 1326-1333
31. Crothers K. Chronic obstructive pulmonary disease in patients who have HIV infection. Clin Chest Med 28 (2007) 575-587
32. Limsukon A., Saeed A., Ramaswamy V., et al. HIV-related pulmonary hypertension. Mt Sinai J Med 73 (2006) 1037-1044
33. Wyatt C., and Klotman P. HIV-associated nephropathy in the era of antiretroviral therapy. Am J Med 120 (2007) 488-492
34. Franceschini N., Napravnik S., Eron Jr. J., et al. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int 67 (2005) 1526-1531
35. Quimby D., and Brito M. Fanconi syndrome associated with use of tenofovir in HIV-infected patients: a case report and review of the literature. AIDS Read 15 (2005) 357-364
36. de Silva T., Post F., Griffin M., et al. HIV-1 infection and the kidney: an evolving challenge in HIV medicine. Mayo Clin Proc 82 (2007) 1103-1116
37. Wyatt C., Arons R., Klotman P., et al. Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality. AIDS 20 (2006) 561-565
38. Heyns C., and Fisher M. The urological management of the patient with acquired immunodeficiency syndrome. BJU Int 95 (2005) 709-716
39. Couzigou C., Daudon M., Meynard J., et al. Urolithiasis in HIV-positive patients treated with atazanavir. Clin Infect Dis 45 (2007) e105-e108
40. Manzardo C., Del Mar Ortega M., Sued O., et al. Central nervous system opportunistic infections in developed countries in the highly active antiretroviral therapy era. J Neurovirol 11 suppl 3 (2005) 72-82
41. Rothman R., Keyl P., McArthur J., et al. A decision guideline for ED utilization of noncontrast head CT in HIV-infected patients. Acad Emerg Med 6 (1999) 1010-1019
42. d'Arminio Monforte A., Sabin C., Phillips A., et al. The changing incidence of AIDS events in patients receiving HAART. Arch Intern Med 165 (2005) 416-423
43. Eng P., Turnbull B., Cook S., et al. Characteristics and antecedents of progressive multifocal leukoencephalopathy in an insured population. Neurology 67 (2006) 884-886
44. Bossolasco S., Calori G., Moretti F., et al. Prognostic significance of JC virus DNA levels in CSF of patients with HIV-associated PML. Clin Infect Dis 40 (2005) 738-744
45. Martinez J., Mazziotti J., Efron E., et al. Immune reconstitution inflammatory syndrome associated with PML in AIDS: a treatable disorder. Neurology 67 (2006) 1692-1694
46. Du Pasquier R., and Koralnik I. Inflammatory reaction in PML: harmful or beneficial?. J Neurovirol 9 suppl 1 (2003) 25-31
47. Kadan-Lottick N., Skluzacek M., and Gurney J. Decreasing incidence rates of primary CNS lymphoma. Cancer 95 (2002) 193-202
48. Jones J., Hanson D., Dworkin M., et al. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. J Acquir Immune Defic Syndr 21 suppl 1 (1999) S11-S17
49. Gerstner E., and Batchelor T. Primary CNS lymphoma. Expert Rev Anticancer Ther 7 (2007) 689-700
50. Rabinstein A. Stroke in HIV-infected patients: a clinical perspective. Cerebrovasc Dis 15 (2003) 37-44
51. Cole J., Pinto A., Hebel J., et al. Acquired immunodeficiency syndrome and the risk of stroke. Stroke 35 (2004) 51-56
52. Ryan C. New black box warning for ritonavir-boosted tipranavir. AIDS Clin Care 18 (2006) 72
53. Ferrari S., Vento S., Monaco S., et al. HIV-associated peripheral neuropathies. Mayo Clin Proc 81 (2006) 213-219
54. Schifitto G., McDermott M., McArthur J., et al. Incidence of and risk factors for HIV-associated distal sensory neuropathy. Neurology 58 (2002) 1764-1768
55. Hahn K., Arendt G., Braun J., et al. A placebo-controlled trial of gabapentin for HIV-associated sensory neuropathies. J Neurol 251 (2004) 1260-1266
56. HIV Neuromuscular Syndrome Study Group. HIV-associated neuromuscular weakness syndrome. AIDS 18 (2004) 1403-1412
57. Mocroft A., Oancea C., van Lunzen J., et al. Decline in esophageal candidiasis and use of antimycotics in European patients with HIV. Am J Gastroenterol 100 (2005) 1446-1454
58. Pulvirenti J., Mehra T., Hafiz I., et al. Epidemiology and outcome of Clostridium difficile infection and diarrhea in HIV infected inpatients. Diagn Microbiol Infect Dis 44 (2002) 325-330
59. Sanchez T., Brooks J., Sullivan P., et al. Bacterial diarrhea in persons with HIV infection, United States, 1999-2002. Clin Infect Dis 41 (2005) 1621-1627
60. Nunez M., Puoti M., Camino N., et al. Treatment of chronic hepatitis B in the human immunodeficiency virus infected patient: present and future. Clin Infect Dis 37 (2003) 1678-1685
61. Monga H., Rodriguez-Barradas M., Breaux K., et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 33 (2001) 240-247
62. De Luca A., Bugarini R., Lepri A., et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected patients. Arch Intern Med 162 (2002) 2125-2132
63. den Brinker M., Wit F., Wertheim-van Dillen P., et al. Hepatitis B and C virus co-infection and the risk of hepatotoxicity highly active anti-retroviral therapy in HIV-1 infection. AIDS 14 (2000) 2895-2902
64. Kottilil S., Polis M., and Kovacs J. HIV infection, hepatitis C infection, and HAART: hard clinical choices. JAMA 292 (2004) 243-250
65. Sullivan P., Hanson D., Chu S., et al. Epidemiology of anemia in HIV-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood 91 (1998) 301-308
66. Volberding P., Levine A., Dietrich D., et al. Anemia in HIV infection: clinical impact and evidence-based management strategies. Clin Infect Dis 38 (2004) 1454-1463
67. Bani-Sadr F., Goderel I., Penalba C., et al. Risk factors for anemia in HIV /hepatitis C virus-coinfected patients treated with interferon plus ribavirin. J Viral Hepat 14 (2007) 639-644
68. Huang S., Barbour J., and Deeks S. Reversal of HIV type-1 associated hematosuppression by effective antiretroviral therapy. Clin Infect Dis 30 (2000) 504-510
69. Klein S., Slim E., de Kruif M., et al. Is chronic HIV infection associate with venous thrombotic disease?. A systematic review. Neth J Med 63 (2005) 129-136
70. Sutor G., Schmidt R., and Albrecht H. Thrombotic microangiopathies and HIV infection: report of two typical cases, features of HUS and TTP, and review of the literature. Infection 27 (1999) 12-15
71. Biggar R., Jaffe E., Goedert J., et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 108 (2006) 3786-3791
72. Silverberg M., and Abrams D. AIDS-defining and non-AIDS defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr Opin Oncol 19 (2007) 446-451
73. Brown T., Cole S., Li X., et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 165 (2005) 1179-1184
74. Bhasin S., Cunningham G., Hayes F., et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 91 (2006) 1995-2010
75. Wunder D., Bersinger N., Fux C., et al. Hypogonadism in HIV-1 infected men is common and does not resolve during antiretroviral therapy. Antivir Ther 12 (2007) 261-265
76. Crum N., Furtek K., Olsen P., et al. A review of hypogonadism and erectile dysfunction among HIV-infected men during the pre- and post-HAART eras: diagnosis, pathogenesis, and management. AIDS Patient Care STDs 19 (2005) 655-671
77. Hoffmann C., and Brown T. Thyroid function abnormalities in HIV-infected patients. Clin Infect Dis 45 (2007) 488-494
78. Angelino A., and Treisman G. Management of psychiatric disorders in patients infected with HIV. Clin Infect Dis 33 (2001) 847-856
79. Ellen S., Judd F., Mijch A., et al. Secondary mania in patients with HIV infection. Aust N Z J Psychiatry 33 (1999) 353-360
80. Arendt G., de Nocker D., von Giesen H., et al. Neuropsychiatric side effects of efavirenz therapy. Expert Opin Drug Saf 6 (2007) 147-154
81. Reveille J. The changing spectrum of rheumatic disease in human immunodeficiency virus infection. Semin Arthritis Rheum 30 (2000) 147-166
82. Marquez J., Restrepo C., Candia L., et al. Human immunodeficiency virus-associated rheumatic disorders in the HAART era. J Rheumatol 31 (2004) 741-746
83. Schwartzman W., Lambertus M., Kennedy C., et al. Staphylococcal pyomyositis in patients infected by the human immunodeficiency virus. Am J Med 90 (1991) 595-600
84. Crum N. Bacterial pyomyositis in the United States. Am J Med 117 (2004) 420-428
85. Calabrese L., Kirchner E., and Shrestha R. Rheumatologic complications of HIV infection in the era of HAART. Semin Arthritis Rheum 35 (2005) 166-174
86. Glesby M. Bone disorders in HIV infection. Clin Infect Dis 37 suppl 2 (2003) S91-S95
87. Prior J., Burdge D., Maan E., et al. Fragility fractures and bone mineral density in HIV positive women: a case-control population based study. Osteoporos Int 18 (2007) 1345-1353
88. Arnsten J., Freeman R., Howard A., et al. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 21 (2007) 617-623
89. Williams D., and Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 41 (2002) 343-370
90. Martins C. Cutaneous drug reactions associated with newer antiretroviral agents. J Drugs Dermatol 5 (2006) 976-982
91. Maurer T., Rodrigues L., Ameli N., et al. The effect of HAART on dermatologic disease in a longitudinal study of HIV-type 1 infected women. Clin Infect Dis 38 (2004) 579-584
92. Zancanaro P., McGirt L., Mamelak A., et al. Cutaneous manifestations of HIV in the era of highly active antiretroviral therapy: an institutional urban clinic experience. J Am Acad Dermatol 54 (2006) 581-588
93. Martin A., Nolan D., Gaudieri S., et al. Predisposition to abacavir hypersensitivity conferred by HLA B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci U S A 101 (2004) 4180-4185
94. Hewitt R. Abacavir hypersensitivity reaction. Clin Infect Dis 34 (2002) 1137-1142
95. Hodgson T., Greenspan D., and Greenspan J. Oral lesions of HIV and HAART in industrialized countries. Adv Dent Res 19 (2006) 57-62
96. Jacobson M., Stanley H., Holtzer C., et al. Natural history and outcome of new AIDS-related cytomegalovirus retinitis diagnosed in the era of HAART. Clin Infect Dis 30 (2000) 231-233
97. Karavellas M., Azen S., MacDonald J., et al. Immune recovery vitritis and uveitis in AIDS: clinical predictors, sequelae, and treatment outcomes. Retina 21 (2001) 1-9